SYRE (Spyre Therapeutics) Cyclically Adjusted PB Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SYRE Spyre Therapeutics Inc SYRE
26 GF Score
Price $102.30
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Spyre Therapeutics  (NAS:SYRE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Spyre Therapeutics Cyclically Adjusted PB Ratio Related Terms


Spyre Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Cyclically Adjusted PB Ratio Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.41 0.46 0.57

Spyre Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.30 0.57 0.82 0.00

SYRE vs CRNX, PTGX, PRAX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Spyre Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spyre Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Cyclically Adjusted PB Ratio falls into.


SYRE
26GF Score
Spyre Therapeutics Inc SYRE
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Spyre Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Spyre Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=11.22/333.9520*333.9520
=11.220

Current CPI (Jun. 2026) = 333.9520.

Spyre Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 126.998 241.428 175.668
201612 117.255 241.432 162.189
201703 106.288 243.801 145.590
201706 95.143 244.955 129.710
201709 84.231 246.819 113.967
201712 75.468 246.524 102.232
201803 65.357 249.554 87.460
201806 83.844 251.989 111.115
201809 72.037 252.439 95.298
201812 69.801 251.233 92.783
201903 100.858 254.202 132.500
201906 86.321 256.143 112.543
201909 68.967 256.759 89.702
201912 51.660 256.974 67.135
202003 36.711 258.115 47.497
202006 85.346 257.797 110.558
202009 76.216 260.280 97.789
202012 72.905 260.474 93.471
202103 63.108 264.877 79.565
202106 60.696 271.696 74.604
202109 51.765 274.310 63.020
202112 42.523 278.802 50.935
202203 31.187 287.504 36.225
202206 34.392 296.311 38.761
202209 27.461 296.808 30.898
202212 19.244 296.797 21.653
202303 12.864 301.836 14.233
202306 -64.003 305.109 -70.053
202309 -60.608 307.789 -65.760
202312 -0.025 306.746 -0.027
202403 -0.892 312.332 -0.954
202406 4.304 314.175 4.575
202409 3.338 315.301 3.535
202412 6.007 315.605 6.356
202503 5.422 319.799 5.662
202506 4.968 322.561 5.143
202509 4.949 324.800 5.088
202512 7.155 324.054 7.374
202603 6.532 330.213 6.606
202606 11.220 333.952 11.220

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Spyre Therapeutics Business Description

Other Exchanges 3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score

Get the complete analysis for SYRE

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$102.30
Price